View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

ACS, Actividades De Construcción y Servicios, S.A.: 1 director

A director at ACS, Actividades De Construcción y Servicios, S.A. sold 75,000 shares at 86.051EUR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

 PRESS RELEASE

Press Release: Sanofi reaches agreement with the US government to lowe...

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump’s four requests, establishing a framework for lower prices for patients in the US and a tariff-free accord for SanofiShowcases commitment to US manufacturing, innovation, and economic growth Paris, December 19, 2025. Sanofi today announced an agreement with President Donald J. Trump's Administration to help ensure American patients ha...

 PRESS RELEASE

Communiqué de presse : Sanofi conclut un accord avec le gouvernement a...

Communiqué de presse : Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation L’accord répond aux quatre demandes du président Trump, établit un cadre pour que les patients américains bénéficient de prix plus bas et exempte Sanofi de droits de douaneL’accord illustre l’engagement de Sanofi à soutenir la production, l’innovation et la croissance économique aux États-Unis Paris, le 19 décembre 2025. Sanofi a an...

Banco Bilbao Vizcaya Argentaria, S.A.: Update following rating upgrade

Our credit view of Banco Bilbao Vizcaya Argentaria, S.A. reflects its strong profitability and high geographical diversification, with an elevated exposure to emerging markets

Luis de Toledo Heras
  • Luis de Toledo Heras
Research Department
  • Research Department

INFORME DIARIO 19 DICIEMBRE (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: FLUIDRA, NATURGY, SECTOR ELÉCTRICO, VIDRALA. EUROPA: KERING. El Ibex recupera los 17.000 puntos Recuperaron el buen tono las bolsas a ambos lados del Atlántico en una jornada marcada por las reuniones del BCE y BoE y el buen dato de inflación en EE.UU. En el STOXX 600, todos los sectores menos Seguros, Farma y Autos terminaron con ganancias, liderados por Retail e Industriales. El BCE mantuvo los tipos de interés inalterados como esperado y mejoró l...

Banco Bilbao Vizcaya Argentaria SA: 1 director

A director at Banco Bilbao Vizcaya Argentaria SA sold 104,451 shares at 19.143EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...

Repsol S.A. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

 PRESS RELEASE

Press release: Availability of the Q4 2025 Aide memoire

Press release: Availability of the Q4 2025 Aide memoire Availability of the Q4 2025 Aide memoire Paris, France – December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's fourth quarter & full year 2025 results will be published on January 29, 2026. About Sanof...

 PRESS RELEASE

Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire...

Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Mise en ligne du document «Q4 2025 Aide mémoire » Paris, France, le 17 décembre 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q4 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du quatrième tri...

 PRESS RELEASE

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in t...

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to developing treatments for rare diseasesEfdoralprin alfa, an investigational restorative recombinant therapy, recently met all primary and key secondary endpoints in phase 2 head-to-head study versus a plasma-derived standard of care Paris, December 17, 2025. The European Medicines Agency...

 PRESS RELEASE

Communiqué de presse : L’efdoralprine alfa de Sanofi obtient la désign...

Communiqué de presse : L’efdoralprine alfa de Sanofi obtient la désignation de médicament orphelin dans l’UE pour l’emphysème lié au déficit en alpha-1-antitrypsine L’efdoralprine alfa de Sanofi obtient la désignation de médicament orphelin dans l’UE pour l’emphysème lié au déficit en alpha-1-antitrypsine Une désignation de médicament orphelin supplémentaire renforce l’engagement de Sanofi à développer des traitements pour les maladies raresL’efdoralprine alfa, un traitement recombinant de restauration expérimental, a récemment satisfait à tous les critères d’évaluation principaux et secon...

Fluidra S.A.: 1 director

A director at Fluidra S.A. bought 151,273 shares at 23.328EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Research Department
  • Research Department

IBERIAN DAILY 15 DECEMBER (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: FERROVIAL, GREENING, REPSOL, TALGO. The Fed continues to underpin stock markets The Fed’s dovish message underpinned the weekly gains of stock markets, conveying confidence on lower rates in 2026 and higher liquidity with the Fed’s short-term asset purchase. This led the Ibex to climb above 17,000 points. In the STOXX 600, Banks and Insurance, closely followed by Travel&Leisure, led the gains whereas Autos and Real Estate were the only sectors ending with drops. On the macro side,...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch